AbbVie Pre-Approval Access to Veliparib for a Patient with Atypical Meningioma
-
- STATUS
- Not Recruiting
Summary
The purpose of this Pre-Approval Access program is to provide an opportunity for your child with atypical meningioma to receive treatment with the investigational drug veliparib, in combination with temozolomide (TMZ).
Description
The purpose of this Pre-Approval Access program is to provide an opportunity for a patient with atypical meningioma to receive treatment with the investigational drug veliparib, in combination with temozolomide (TMZ). At this time there are no other treatment options for this patient; this is a compassionate use application.
Details
| Condition | Atypical Meningioma |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX8402 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.